Health ❯Healthcare ❯Regulatory Agencies
Pharmaceuticals Clinical Trials Regulatory Affairs Regulatory Agencies Treatment Protocols Market Analysis Market Trends Oncology Drug Development
The MHRA authorizes Blenrep for relapsed or refractory multiple myeloma based on pivotal Phase 3 trial data, with reviews underway in 14 countries.
